San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, BlossomHill Therapeutics is raising $70,999,993.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Jingrong JeanCui played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About BlossomHill Therapeutics

BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders. The company is founded by renowned drug design and development scientist, J. Jean Cui, Ph.D., and biotech business veteran, Y. Peter Li, Ph.D., M.B.A. BlossomHill Therapeutics, Inc. is headquartered in San Diego, California.

To learn more about BlossomHill Therapeutics, visit http://bhtherapeutics.com/

Contact:
Jingrong JeanCui, President and Chief Executive Officer
650-302-8388
https://www.linkedin.com/in/jingrong-jean-cui-9b83a817/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved